Xenon Pharmaceuticals Inc. | Mid-cap | Healthcare

Xenon Performance Comparison

Loading chart data...

Stock Range

Today's Range

Low: $31.65 High: $33.51
on July 9, 2025

52 Week Range

Low: $26.74 High: $46.00
on April 9, 2025
on November 8, 2024

All-Time High: $50.99 on February 26, 2024

Explore how other US stocks compare to their 52-week ranges: View US Market 52-Week Insights

Key Statistics

Market Cap i $2.4B
EPS i N/A
P/E Ratio (TTM) i N/A
Forward P/E i -8.95
P/B Ratio i 3.47
PEG Ratio i -8.95
Div. Yield i N/A
ROE i -31.60%
Beta i N/A
Debt to Equity i 1.23

Financial Highlights

Profitability

Gross Margin i N/A
Operating Margin i N/A
Profit Margin i N/A

Returns and Earnings

Return on Assets (TTM) i N/A
Return on Equity (TTM) i -31.60%
EBITDA i N/A
Net Income (TTM) i N/A

Growth

Revenue (TTM) i
Revenue Per Share (TTM) i
Quarterly Revenue Growth i N/A
Quarterly Earnings Growth i N/A

Peer Performance Comparison

Performance comparison table showing returns for peer companies over various time periods
CompanyMarket Cap1W1M3M6MYTD1Y3Y5Y
Xenon XENE 2.45B Mid-cap-2.07%3.91%3.45%-14.92%-18.65%-26.79%-2.39%156.28%
Vertex VRTX 114.06B Large-cap4.80%7.35%-0.69%16.95%18.04%-4.58%59.25%58.34%
Regeneron REGN 55.27B Large-cap0.88%6.76%-4.19%-20.71%-22.74%-50.21%-9.84%-14.95%
Blueprint Medicines BPMC 8.30B Mid-cap0.27%0.45%56.67%47.03%47.42%9.02%139.78%65.31%
Roivant Sciences ROIV 7.82B Mid-cap2.28%1.26%13.45%5.55%-7.12%-4.32%154.33%9.48%
Bio-Techne TECH 7.92B Mid-cap-1.11%5.43%-2.74%-28.26%-26.43%-31.86%-38.81%-24.68%

Ownership & Short Interest

Insider Ownership i 0.26%
Institutional Ownership i 103.59%
Shares Short i 3M
Short Ratio i 2.34
Short % of Shares Outstanding i 4.89%
Average 10-Day Volume i 724K
Average 90-Day Volume i 1M

Xenon Recurring Investment / Dollar-Cost Averaging Calculator

Calculate how a regular investment in Xenon would have performed over time.

$
If not specified, the latest available data will be used

Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.

Frequently Asked Questions

What is XENE's 52-week high and low?

In the last 52 weeks, Xenon reached a high of $46.00 (on November 8, 2024) and a low of $26.74 (on April 9, 2025).

What is the market cap and P/E ratio for XENE?

Curious about Xenon's size and valuation? Its market capitalization stands at 2.45B. When it comes to valuation, the P/E ratio (trailing twelve months) is N/A, and the forward P/E (looking ahead) is -8.95.

Does XENE pay dividends? If so, what's the yield?

As for dividends, Xenon isn't currently offering a significant yield, or that specific data isn't available right now.

Who are Xenon's main competitors or similar companies to consider before investing?

When looking at Xenon, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:

CompanyMkt CapSectorIndustry1Y Return3Y Return
Vertex
VRTX
114.06BHealthcareBiotechnology-4.58%59.25%
Regeneron
REGN
55.27BHealthcareBiotechnology-50.21%-9.84%
Blueprint Medicines
BPMC
8.30BHealthcareBiotechnology9.02%139.78%
Roivant Sciences
ROIV
7.82BHealthcareBiotechnology-4.32%154.33%
Bio-Techne
TECH
7.92BHealthcareBiotechnology-31.86%-38.81%

For a more comprehensive list, please see the Peer Performance Comparison table on this page.

What are the key financial health indicators for Xenon Pharmaceuticals Inc.? (e.g., ROE, Debt/Equity)

To get a sense of Xenon's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is -31.60%, the Debt to Equity ratio from the most recent quarter is 1.23, and its Gross Profit Margin stands at N/A.

What is the recent revenue and earnings growth for XENE?

Looking at Xenon's growth, its revenue over the trailing twelve months (TTM) was $8M. Compared to the same quarter last year (YoY), quarterly revenue grew by N/A, and quarterly earnings saw a YoY growth of N/A.

How much of XENE stock is held by insiders and institutions?

Wondering who owns Xenon stock? Company insiders (like executives and directors) hold about 0.26% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 103.59%.

For more common questions about our data, please visit our About Data page.

Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.